Dr. Svenja Dannewitz Prosseda is an accomplished engineer, cell biologist, and immunologist. She has a strong educational background from renowned academic institutions including the Universities of Cambridge, Manchester, Sheffield, and Stanford University. With a focus on cell biology and medicine, she consistently publishes impactful research in international peer-reviewed journals, with an impressive cumulative IF score of over 100. Dr. Dannewitz Prosseda's expertise lies in understanding the regulation of cellular function through vascular flow and the microenvironment. Her groundbreaking doctoral work provides valuable insights into the modulation of immune cell survival by microenvironmental stimuli. Notably, she holds a patent for a pharmaceutical strategy targeting Pulmonary Arterial Hypertension, acquired by Denovo Pharma in 2019. In addition to her research contributions, Dr. Dannewitz Prosseda has served as a scientific editor for Cactus Communications and currently acts as a peer-reviewer for various MDPI journals. Committed to fostering the growth of junior scientists and students, she actively supports them through lectures, online courses, and direct supervision.
Scientific Reviewer for biomedical science manuscripts
Designed lecture for Critical Thinking